Related Experiment Videos

Hypercalcemia in the accelerated phase of chronic myelogenous leukemia

Cancer
|September 1, 1980
PubMed

Insights

Severe hypercalcemia can occur in accelerated phase chronic myelogenous leukemia and is not caused by parathyroid hormone. Mithramycin may be an effective treatment when saline diuresis is insufficient.

Area of Science:

  • Hematology
  • Oncology
  • Endocrinology

Background:

  • Chronic myelogenous leukemia (CML) is a myeloproliferative neoplasm.
  • Accelerated phase CML presents unique clinical challenges.
  • Hypercalcemia is a potential complication in advanced malignancies.

Observation:

  • Three patients with accelerated phase CML presented with severe hypercalcemia.
  • In two patients, hypercalcemia was confirmed with suppressed parathyroid hormone (PTH) levels.

Findings:

  • Hypercalcemia in accelerated phase CML may be more prevalent than previously recognized.
  • The hypercalcemia observed was not PTH-mediated.
  • Elevated PTH levels in this context warrant investigation for primary hyperparathyroidism.

Implications:

  • This finding necessitates increased awareness of hypercalcemia in accelerated phase CML.
  • Non-PTH-mediated hypercalcemia requires specific management strategies.
  • Mithramycin should be considered early for refractory hypercalcemia in CML, especially when saline diuresis is inadequate.

Related Concept Videos